BridgeMD
New treatment option for Rectal Cancer
Official title Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)
ClinicalTrials.gov ID: NCT07098182
What this study is testing
- What it's testing
- Colorectal cancers and ovarian cancers are respectively the 2nd and 5th cause of cancer mortality in France. Surgical resection is a crucial step in the therapeutic management of colorectal cancers.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male/ female aged over 18 years,
- Histologically proven left colon or rectal adenocarcinoma OR ovarian carcinoma (with potential colorectal resection),
- Scheduled surgery for left colic or rectal carcinoma// Scheduled surgery for ovarian carcinoma with potential colorectal resection,
- Surgical indication of colo-rectal resection validated in RCP and confirmed during the operative exploration (ovarian cancer,
- WHO Status \< 3
You likely can't join if
- Contraindication to indocyanine green: thyroid adenoma, hyperthyroidism, hypersensitivity or allergy to one of the components, severe renal failure...
- Patient with a history of abdominal vascular surgery
- Patient (e) not having left colic artery on vascular mapping of preoperative abdominal-pelvic scanners,
- Patient whose regular follow-up is not possible for psychological, family, social or geographical reasons,
- Patient (s) under guardianship, curatorship or safeguard of justice,
- Pregnant and/or breastfeeding patient,
See the full eligibility criteria
- Male/ female aged over 18 years,
- Histologically proven left colon or rectal adenocarcinoma OR ovarian carcinoma (with potential colorectal resection),
- Scheduled surgery for left colic or rectal carcinoma// Scheduled surgery for ovarian carcinoma with potential colorectal resection,
- Surgical indication of colo-rectal resection validated in RCP and confirmed during the operative exploration (ovarian cancer,
- WHO Status \< 3
- Patient who has given informed, written and express consent,
- Patient (s) affiliated to a French social security.
- Contraindication to indocyanine green: thyroid adenoma, hyperthyroidism, hypersensitivity or allergy to one of the components, severe renal failure (GFR \<30 ml/min/1.73m2),
- Patient with a history of abdominal vascular surgery
- Patient (e) not having left colic artery on vascular mapping of preoperative abdominal-pelvic scanners,
- Patient whose regular follow-up is not possible for psychological, family, social or geographical reasons,
- Patient (s) under guardianship, curatorship or safeguard of justice,
- Pregnant and/or breastfeeding patient,
The study team makes the final eligibility decision.
Where it's taking place
- Montpellier, Herault, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montpellier, Herault, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.